Immunogenicity, Tolerability, and Clinical Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus

The aim of the work is to study the immunogenicity, tolerability, and clinical efficacy of the 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with systemic lupus erythematosus (SLE). Material and methods. The study included 61 patients with a confirmed diagnosis of SLE, including 53 women, 8 men, aged 19 to 68 years. The disease activity at the time of vaccination: in 9 patients — high, in 13 — medium, in 34 — low, in 5 — remission. Therapy outline: 59 patients received glucocorticoids (GC) 5–30 mg/day in terms of prednisolone, 45 — hydroxychloroquine (GC), 33 — cytostatics (CS), 22 — genetically engineered biological drugs (GEBD): 11 — rituximab (RTM), 10 — belimumab (BLM). 23-valent polysaccharide pneumococcal vaccine in an amount of 0.5 ml (1 dose) was injected subcutaneously. Follow-up period: 9 patients — 3 months, 52 — 1 year after the vaccination. Patients were examined before vaccination, as well as in 1, 3, and 12 months after the vaccination. Results and discussion. After a year of observation, the number of «responders» to vaccination was 61.5%, «non-responders» — 38.5%. There was a decreased response to vaccine in patients receiving GEBD compared with patients who did not receive GEBD (40% and 75%, respectively), p=0.02. No differences were found against the background of RTM and BLM therapy. Administering GC in a dose exceeding 10 mg/day did not lead to a more significant decrease in response to vaccine compared to other patients. Standard local vaccination reactions of mild to moderate severity were noted in 50.8% of the patients, general reaction of mild severity — in 1 patient (1.6%), hyperergic Arthus-like reaction — in 1 patient (1.6%), the symptoms of which were relieved in 7 days. During the observation period (1 year), not a single case of exacerbation of SLE, reliably associated with the vaccination, was registered, and no new autoimmune phenomena were identified. Clinically positive dynamics was noted in the form of a decrease in the number of episodes of pneumonia, as well as acute and exacerbated chronic bronchitis, sinusitis. Conclusion. Sufficient immunogenicity, good tolerance, and clinical effectiveness of PPV-23 in patients with SLE, incl. those, who received combined immunosuppressive therapy. Further studies are needed in large groups of patients with long follow-up periods.

1. Доступно по ссылке: https://yaprivit.ru/diseases/pnevmokokkovayainfekciya

2. ПОЛЯНСКАЯ М.В. Пневмония у пациентов с ревматическими заболеваниями: частота встречаемости, клиническая картина, факторы риска: Автореф. дис. … канд. мед. наук. М.: 2009. — 24 с. / Polyanskaya M.V. / Pneumonia in patients with rheumatic diseases: frequency of occurrence, clinical picture, risk factors: Author's abstract. Dis. ... PhD in Medicine]. Moscow; 2009. 24 p. [in Russian].

3. Tektonidou M.G., Lewandowski L.B., Hu J. et al. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis 2017 Dec; 76 (12): 2009–2016. doi: 10.1136/annrheumdis2017-211663

4. Moss K.E., Ioannou Y., Sultan S.M. et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002; 61: 409–413. doi: 10.1136/ard.61.5.409

5. Nossent J., Cices N., Kiss E. et al. Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual. Lupus 2007;16: 309–317. doi: 10.1177/0961203307077987

6. Van Assen S., Agmon-Levin N., Elkayam O. et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70 (3): 414–422. doi: 10.1136/ard.2010.137216

7. Furer V., Rondaan C., Heijstek M.W. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79 (1): 39–52. doi:10.1136/annrheumdis-2019-215882

8. Petri M., Orbai A.M., Alarcon G.S. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64 (8): 2677–286. doi: 10.1002/art.34473.

9. Gladman D.D., Ibañez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29 (2): 288–291.

10. Nguyen M., Lindegaard H., Hendricks O., Friis-MОller N. Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA). Scand J Rheumatol 2017 Nov; 46 (6): 446–453. doi: 10.1080/03009742.2016.1242774

11. Loubet P., Kerneis S., Groh M. et al. Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine 2015; 33 (31): 3703–3708. doi: 10.1016/j.vaccine.2015.06.012

12. Subesinghe S., Rutherford A.I., Ibrahim F. et al. A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. BMC Musculoskelet Disord 2016; 17: 322. doi: 10.1186/s12891-016-1187-4

13. НАУМЦЕВА М.С., БЕЛОВ Б.С., АЛЕКСАНДРОВА Е.Н. И ДР. Иммуногенность и безопасность 23-валентной полисахаридной пневмококковой вакцины у больных ревматоидным артритом: результаты двухлетнего наблюдения. Научно-практическая ревматология. — 2016. — Т. 54. — № 6. — С. 674–680. / Naumtseva M.S., Belov B.S., Aleksandrova E.N. et al. Immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with rheumatoid arthritis: Results of a two-year follow-up study. Nauchno-Prakticheskaya Revmtologiya. Rheumatology Science and Practice 2016; 54 (6): 674–680 [in Russian]. doi: 10.14412/1995-4484-2016-674-680.

14. Bukhanova D., Sergeeva M., Belov B. et al. Immunogenicity and safety of 23-valent pneumococcal vaccine in ra patients: results of a 4- year follow up study. Ann Rheum Dis 2018; 77 Suppl 2: 1060. doi: 10.1136/annrheumdis-2018-eular.1586

15. Bukhanova D., Belov B., Tarasova G. et al. Immunogenicity and safety of 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results from 5-year follow up. Ann Rheum Dis 2019; 78 (Suppl 2): 336. doi: 10.1136/annrheumdis-2019-eular.3173

16. Tarasova G., Belov B., Bukhanova D. et al. Use of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus: the relationship of immunogenicity with therapy. Ann Rheum Dis 2019, 78 (Suppl 2): 785–786. doi: 10.1136/annrheumdis-2019-eular.3646

17. Elkayam O., Paran D., Caspi D. et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002; 34 (2): 147–153. doi: 10.1086/338043.

18. Hua C., Barnetche T., Combe B., Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2014 Jul; 66 (7): 1016–1026. doi: 10.1002/acr.22246

19. Crnkic Kapetanovic M., Saxne T., Jönsson G. et al. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther 2013; 15 (5): R171. doi: 10.1186/ar4358

20. Binder M., Otto F., Mertelsmann R. et al. The epitope recognized by rituximab. Blood 2006; 108 (6): 1975–1978. doi: 10.1182/blood-2006-04-014639

21. МАСЛЯНСКИЙ А.Л., МАЗУРОВ В.И., ЗОТКИН Е.Г. Анти-В-клеточная терапия аутоиммунных заболеваний. Медицинская иммунология. — 2007. — Т. 9. — № 1. — С. 15–34 / Maslyanskij A.L., Mazurov V.I., Zotkin E.G. Anti-B-cell therapy for autoimmune diseases. Medicinskaya Immunologiya 2007; 9 (1): 15–34 [in Russian]

22. Centers for Disease Control (CDC). Pneumococcal polysaccharide vaccine. Morb Mortal Wkly Rep 1989; 38 (5): 64–68, 73–76.

23. Pugès M., Biscay P., Barnetche T. et al. Immunogenicity and impact on diseaseactivity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology 2016; 55 (9): 1664–1672. doi: 10.1093/rheumatology/kew211.

24. Chang C.C., Chang Y.S., Chen W.S. et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Sci Rep 2016; 6: 37817. doi: 10.1038/srep37817.

25. Bühler S., Eperon G., Ribi C. et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly 2015 Jul 28; 145: w14159. doi: 10.4414/smw.2015.14159

26. КОЗЛОВ Р. С. Современные возможности специфической профилактики пневмококковых инфекций. Клиническая микробиология и антимикробная химиотер. — 2002. — Т. 4. — № 1. — С. 61–69. / Kozlov R. S. Sovremennye vozmozhnosti specificheskoj profilaktiki pnevmokokkovyh infekcij. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioter 2002; 4 (1): 61–69. [in Russian]